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Abstract
Background: There is increasing evidence for the role of High Risk (HR) Human PapillomaVirus (HPV) in the
pathogenesis of Oral Squamous Cell Carcinoma (OSCC). The E6 and E7 oncogenes from HR HPVs are responsible
for the deregulation of p53 and pRB proteins involved in cell cycle and apoptotic pathways. In cell lines
experiments, the HPV E7 protein seems to be able to enhance Hypoxia Inducible Factor-1 alpha (HIF-1a) activity,
normally involved in the response to hypoxia and able to enhance angiogenesis.
Results: We studied tumor specimens from 62 OSCC; a higher prevalence of tumors in TNM stage II and also in
pT2 class between OSCC infected positive HPV16 DNA than non-infected ones was observed. HIF-1a positivity was
detected throughout the analysed fields, not associated with areas of necrosis and also observed in cells
immediately adjacent to blood vessels. A significant increase in mean values of the HIF-1a labeling indexes was
observed for pT1-T2, as well for stage I-II, in the infected positive HPV16 DNA tumors than non-infected ones. HIF-
1a and HPV16 E7 labeling indexes showed a significantly positive correlation which suggested a positive
association between HPV16 E7 and HIF-1a expression.
Conclusions: In our specimens HIF-1a immunoreactivity hints for an O2-independent regulatory mechanism in
infected positive HPV16 DNA tumors, especially for pT1-T2 and stage I-II tumors, suggesting a very early
involvement in the development of HPV-induced OSCC. HIF-1a and HPV16 E7 labeling indexes suggest also a
positive association between the two proteins in infected positive HPV16 DNA OSCC.
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Background
Nowadays there is increasing evidence for the role of
high risk (HR) Human PapillomaVirus (HPV) in the
pathogenesis of Oral Squamous Cell Carcinoma (OSCC)
[1-7], till to consider HPV positive (HPV+) OSCC as a
distinct clinicopathological entity with a different out-
come in comparison with HPV negative (HPV-) OSCC
[2,6,8-11]. The HR types HPV16, 18, 31 and others, are
frequently found in cervical cancers and have been
found to be risk factors also for OSCC, independently
from alcohol and tobacco use [2,12-16]. HPV16, the
most common HR HPV type detected in biopsies from
women with cervical squamous cell carcinoma (55%)
[17,18], was also the most common type detected in
OSCC (16%), accounted for 68.2% of all HPV+ OSCC
[19,20].
The E6 and E7 oncogenes from HR HPVs are respon-
sible for maintaining differentiating cells active in cell
cycling and are able to transform both cervical and
upper aero-digestive tract epithelia via expression of the
viral oncoproteins E6 and E7 and the following deregu-
lation of cell cycle and apoptotic pathways [21,22].
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These 2 proteins promote the degradation of cellular
tumor suppressors: p53 in the case of E6 and pRb family
members in the case of E7. Binding and degradation of
pRb family members by E7 results in the release of E2F
transcription factors that in turn drive the cell into S
phase. The abrogation of pRb function by HR E7 pro-
teins induces a stress response leading to an elevated
activity of p53, which can in turn induce apoptosis [23].
But the high-risk E6 proteins degrade p53, thus prevent-
ing apoptosis and allowing continued proliferation. In
addition to these well-known activities, both proteins
have a wide range of other targets [23], and the extent
to which these additional interactions contribute to
HPV-associated carcinogenesis is not fully understood.
Among the additional factors bound by E7 are histone
deacetylases (HDAC), which catalyze the deacetylation
of histones and other transcriptional regulatory proteins
[24].
One important characteristic of both benign and
malignant lesions is the ability to promote angiogenesis,
which allows a growing lesion to access nutrients and
oxygen for growth [25]. Angiogenesis is mainly triggered
by hypoxia or reduced tissue oxygen levels. The cellular
response to hypoxia is primarily regulated through the
activity of the transcription factor Hypoxia-Inducible
Factor-1 (HIF-1) [26,27]. HIF-1 consists of a heterodi-
mer of two proteins (HIF-1a and HIF-1b) which med-
iates the transcription activation of several genes
involved in stress response [28]; under normal oxygen
conditions (normoxia), the HIF-1a subunit has a very
short half-life due to oxygen-dependent hydroxylation
and consequent degradation through the von Hippel-
Lindau (VHL)/proteasome pathway; under hypoxic con-
ditions, reduced oxygen levels result in the accumulation
of HIF-1a, which translocates to the nucleus and leads
to the accumulation of functional HIF-1 Transcription
Factors that in turn activate the expression of HIF-1 tar-
get genes, including a range of proangiogenic factors
and enzymes that favor glycolytic over aerobic metabo-
lism [27]. In addition to this hypoxia-dependent stabili-
zation system, a range of other post translational
modifications and signaling pathways, also affect HIF-1a
synthesis, stability, and activity such as the p53, p300/
CBP, and several HDACs [29-31].
Recent studies indicate that, in cell lines experiments,
the HPV E7 protein is responsible for enhanced HIF-1a
activity and enhances HIF-1 dependent transcription by
inducing the dissociation of HDACs from HIF-1a [32].
The aim of this study was to examine the HIF-1a pro-
tein expression in OSCC to test the hypothesis that
HPV E7 protein may influence HIF-1a expression in
OSCC infected positive for HPV16 DNA.
Results
Characteristics of the Study Population
We studied tumor specimens from 62 OSCC; clinico-
pathological characteristics for non-infected (Group I)
vs. infected positive HPV16 DNA tumors (Group II)
are detailed in Table 1. The two groups of tumors did
not differ statistically significantly with regard to
patient age at diagnosis, sex, site, histological grading;
instead, statistically significant differences were found
regarding TNM stage (p < .001) and tumor size (p <
.001): in particular a higher prevalence of tumors in
TNM stage II between OSCC infected positive HPV16
DNA (76.9%) than non-infected ones (23.1%) was
observed and refining the components of TNM sta-
ging, also in pT2 class (73.3% infected positive HPV16
DNA tumors).
Table 1 Comparison of clinico-pathological parameters in
HPV- DNA (group I) and HPV16+ DNA (group II) oral
squamous cell carcinomas
Parameters Group I
(HPV-)
(%)
n.39 Group II
(HPV16+)
(%)
n.23 p
value*
Age at diagnosis, year
< 53 (10) 4 (4) 1
53-73 (54) 21 (70) 16
> 73 (36) 14 (26) 6 N.S
Sex
Female (46) 18 (43) 10
Male (54) 21 (57) 13 N.S.
Site of primary tumor
Tongue (46) 18 (48) 11
Buccal Mucosa (26) 10 (22) 5
Alveolar Ridge Mucosa (18) 7 (17) 4
Palate (10) 4 (13) 3 N.S.
Tumor Histological Grade
Well (G1) (57) 22 (65) 15
Moderate (G2) (28) 11 (26) 6
Poor (G3) (15) 6 (9) 2 N.S.
TNM Stage
I (64) 25 (22) 5
II (8) 3 (44) 10
III (13) 5 (30) 7
IV (15) 6 (4) 1 < .001
pT
1 (64) 25 (22) 5
2 (10) 4 (48) 11
3 (10) 4 (26) 6
4 (16) 6 (4) 1 < .001
* Chi-square test and Fisher’s exact test; statistical results were considered
significant for p values < .05 (N.S. indicates not significant)
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Immunohistochemical analysis of HPV16 E7 oncoprotein
It was analyzed whether high-risk HPV16 E7 oncopro-
tein were detectable by immunohistochemical analysis.
No HPV16 E7 oncoprotein staining could be detected in
the 39 specimens from tumors negative for HPV DNA
as expected; instead in the 23 tumors positive for
HPV16 DNA, the affinity-purified monoclonal anti-
HPV16 E7 antibody recognized almost all epithelial cells
within the tumor islets (Figure 1A, B) but did not stain
any cells in the adjacent connective tissues. Dysplastic
tumor cells in precancerous squamous epithelium adja-
cent to the cancerous tumor islets in the same section
were also positively stained. Keratinocytes in areas of
non-neoplastic squamous epithelium were not stained.
In keeping with a previous study [33], these findings
suggest that E7 can be considered as a marker for pre-
malignant intraepithelial lesions. Whereas all HPV16
DNA positive carcinomas stained positive for E7, a
more detailed analysis revealed strong variations in E7
oncoprotein expression levels with labeling indexes ran-
ged from 32.6% to 100% (mean 77.15 ± 25.01). Because
there was only one case in pT4 class and in stage IV, we
chose to dichotomize size as pT3 and pT4 vs. pT1 and
pT2 as well stage TNM III and IV vs. I and II. In the
pT1-T2 group, E7 oncoprotein labeling indexes ranged
from 32.6% to 95.4% (mean 68.73 ± 19.89); in the pT3-
T4 group, E7 oncoprotein labeling indexes ranged from
83,8% to 100% (mean 96.4 ± 6.01); these differences
proved to be significant (p < .001) (Figure 2). Similar
results were also obtained for stages groups [Stage I-II
labeling indexes from 32.6% to 96.6% (mean 66.96 ±
19.23); Stage III-IV from 83.8% to 100% (mean 96.27 ±
5.57); p < .001]. No significant differences were found
for age, sex, site or histological grading (data not
shown).
HIF-1a expression is increased in infected positive HPV16
DNA tumors
Immunohistochemical staining was also performed to
identify the presence of the HIF-1a protein; immunor-
eaction was revealed in all cases but two of the non-
infected group, both of them were very small tumors
(pT1 of mm 4 and mm 5, TNM stage I) of the tongue.
In our specimens HIF-1a positivity was detected
throughout the analysed fields, not associated with areas
of necrosis and also observed in cells immediately adja-
cent to blood vessels. Adjacent non-neoplastic tissue,
the stromal and normal cells did not show immunoreac-
tivity for HIF-1a. In the 62 tumor’s specimens investi-
gated, the labeling indexes ranged from 0% to 94.5%
(mean 45.26 ± 26.6). No significant differences for mean
value of HIF-1a labeling indexes were found for age,
sex, site or histological grading; however the labeling
indexes showed a significant increase in mean values for
pT1-T2 tumors vs. pT3-T4 (33.02 ± 19.66 vs. 77.65 ±
9.93; p = .015), as well for Stage I-II vs. Stage III-IV
(31.41 ± 18.53 vs. 76.6 ± 10.12; p = .03).
Generally, immunoreactivity for HIF-1a was detected
with intense cytoplasmatic and nuclear positivity in
tumor cells of cases with positive HPV16 DNA (Group
Figure 1 Representative images of HPV16 E7 oncoprotein and
HIF-1a protein immunostaining of paraffin sections from oral
squamous cell carcinomas. A) Tumor positive for HPV16 DNA with
almost all epithelial tumor cells stained positive for E7; B) tumor
negative for HPV DNA with no HPV16 E7 oncoprotein staining; C)
Consecutive section of the same specimen of tumor positive for
HPV16 DNA represented in “A)”, stained with the anti-HIF-1a
antibody: uniform location of immunoreactivity for HIF-1a and
HPV16 E7 on the same tumor; D) weak expression for HIF-1a in
tumor cells of tumor negative for HPV DNA (magnifications × 200;
scale bars 100 μm).
Figure 2 Labeling indexes immunoreactivity for HIF-1a in
paraffin sections from oral squamous cell carcinomas. A lower
HIF-1a protein expression was observed in tumors negative for HPV
DNA in comparison with those positive for HPV16 DNA (37.24 ±
25.95 vs. 58.85 ± 22.17; p < .001). Differences were analyzed by the
Mann-Whitney test; statistical results were considered significant for
p values < .05.
Rodolico et al. Infectious Agents and Cancer 2011, 6:18
http://www.infectagentscancer.com/content/6/1/18
Page 3 of 8
II) (Figure 1C), whereas a weak cytoplasmatic expression
was found in tumor cells of the non-infected group
(Group I) (Figure 1D), similar to the one found in some
of the islet of precancerous squamous epithelium adja-
cent to the infected positive HPV16 DNA tumors
(Group II).
In the positive HPV16 DNA tumors (Group II), the
HIF-1a labeling indexes ranged from 21.7% to 94.5%
(mean 58.85 ± 22.17), while in the non-infected group
(Group I), ranged from 0% to 85% (mean 37.24 ±
25.95); these differences proved to be significant (p <
.001) (Figure 2).
On examining the mean values of the HIF-1a labeling
indexes between Group II and Group I, significant dif-
ferences were not found for age, sex, site or histological
grading; however, statistical analysis demonstrated for
pT1-T2 tumors a significant increase in mean values of
the HIF-1a labeling indexes in the infected positive
HPV16 DNA tumors (48.31 ± 17.14) than non-infected
tumors [(24.59 ± 15.58); p < .001], as well for stage I-II
tumors [(46.59 ± 16.24 mean value of the HIF-1a label-
ing indexes in Group II; 23.28 ± 14.17 mean values in
Group I); p < .001]. The same analysis for pT3-T4
group of tumors [(82.94 ± 9.77 mean values of the HIF-
1a labeling indexes in Group II; 73.96 ± 8.64 mean
values in Group I); p = .07] as well for stage III-IV
[(81.85 ± 9.56 mean values of the HIF-1a labeling
indexes in Group II; 72.78 ± 9.08 mean values in Group
I); p = .05] did not showed significant differences in
mean values of the HIF-1a labeling indexes between
Group II and Group I (Figure 3).
Interestingly, HIF-1a and HPV16 E7 immunoreactivity
were uniform in location on the same tumor (Figure 1A
and 1C), and their labeling indexes showed a signifi-
cantly positive correlation (Rho = .512; p < .001), which
suggested a positive association between HPV16 E7 and
HIF-1a expression (Figure 4). A more detailed analysis
showed a stronger positive association between the two
proteins in pT1-T2 group than in pT3-T4 [(pT1-T2
tumors: Rho = .669; p < .001) (pT3-T4: Rho = .494; p =
.04)] and stage I-II tumors than stage III-IV [(stage I-II
tumors: Rho = .684; p < .001) (III-IV: Rho = .510; p =
.02)].
Discussion
Several studies have investigated the role of HPV in oral
carcinogenesis, confirming that HPV plays a role in oral
carcinogenesis and HPV cancers are specific type of
tumors with numerous important differences reported
in typology of risk patient (generally, never married
younger males, < 40 yrs.), histological grading (well dif-
ferentiated cancer), histotype (possible but not necessary
basaloid appearance with a characteristic faster growing)
and clinical outcome in term of overall survival (patients
with HPV-positive OSCC had a lower risk of dying and
a lower risk of recurrence than HPV-negative OSCC
patients) [34-37]. However, the protective mechanism by
which HPV infection improves the overall survival and
prognosis in oral cancer is not yet clearly understood.
HPV16, the most common HR HPV type detected in
biopsies from women with cervical SCC (55%) [17,18],
was also the most common type detected in OSCC
(16%), accounted for 68.2% of all HPV+ OSCC [19,20].
Figure 3 Labeling indexes immunoreactivity for HIF-1a in pT1-
T2 and pT3-T4 oral squamous cell carcinomas. pT1-T2 tumors
showed a significant increase in mean values of the HIF-1a labeling
indexes in infected positive HPV16 DNA tumors than non-infected
tumors (48.31 ± 17.14 vs. 24.59 ± 15.58; p < .001); pT3-T4 tumors
did not showed significant differences in mean values of the HIF-1a
labeling indexes between infected positive HPV16 DNA tumors and
non-infected tumors (82.94 ± 9.77 vs. 73.96 ± 8.64; p = .07).
Differences were analyzed by the Mann-Whitney test; statistical
results were considered significant for p values < .05.
Figure 4 Bivariate scatter plot of HPV16 E7 and HIF-1a
labeling indexes in infected positive HPV16 DNA tumors.
Significantly positive correlation between HPV16 E7 and HIF-1a
expression (Rho = .512; p < .001. Correlations among continuous
variables and p values were determined by using the Spearman
test; statistical results were considered significant for p values < .05.
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In our own study, a higher prevalence of OSCC in
TNM stage II was found among infected positive
HPV16 DNA tumors than non-infected tumor ones and,
refining better the components of TNM staging, a
higher prevalence was also found for HPV status in
OSCC pT2. The prevalence of OSCC in stage II and
pT2 class positively infected by HPV16 could be reason-
ably explained by their faster growing and higher prolif-
erative activity than negative HPV ones, as also
observed in studies investigating markers of prolifera-
tion, such as the proliferating cell nuclear antigen
(PCNA) [38].
The HR HPV types that infect the genital mucosa
typically last from 12-18 months and are eventually
cleared by the immune system [39]. Approximately 10%
of women fail to clear HPV infections, resulting in long-
term persistent infection [40]. Maintenance of the viral
episome in basal cells is the basic function of the early,
or maintenance, phase of the viral life cycle. E6, E7, E1
and E2 are each necessary for continued episomal main-
tenance of whole genomes in cell culture [41]. HPVs
exert their oncogenic role after DNA integration, gene
expression of E5, E6 and E7 loci and p53/pRb host pro-
teins suppression, leading to increased cell proliferation
and contributing to carcinogenesis [42,43].
In the present study, the detection of the E7 oncopro-
tein always coincided with the presence of an invasive
OSCC positive for HPV16 DNA; when we compared
the E7 oncoprotein expression with the clinico-patholo-
gic characteristics of these lesions, we found an associa-
tion between E7 oncoprotein expression and TNM stage
and tumor size. There is strong evidence that expression
of the E7 oncogene is necessary for the induction and
maintenance of the transformed phenotype [44]; how-
ever, the role of the E7 oncoprotein in OSCC has
remained elusive. In this study, we analyzed for the first
time the high-risk E7 oncoprotein expression in OSCC
infected positive HPV16 DNA and we report the pre-
sence of high-risk HPV oncoprotein in all of these
OSCC cancer specimens. These findings indicate that
the high-risk E7 oncoproteins of HPV16 is expressed
continuously in invasive HPV16 DNA positive OSCC.
As HPVs lesions persist they become larger and exhi-
bit increased requirements for nutrients. In proliferating
lesions there is competition between cells for nutrients
and oxygen, and this can result in arrest of cellular pro-
liferation or even cell death. HPV lesions overcome this
constraint by promoting angiogenesis [45-47]. In many
cancers, angiogenesis occurs only late in tumor progres-
sion, but increased vascular density and production of
angiogenic factors is a very early event in the develop-
ment of HPV-induced pre-malignant lesions and cervi-
cal cancers [46,47]. Furthermore, several studies have
reported that HPV gene products can induce the pro-
duction of angiogenic factors from infected cells [48-51].
Transient transfection of E6 and E7 expression vectors
into cervical cancer cell lines was reported to induce
higher HIF-1a levels under normoxic conditions [48].
Others studies indicate that cells containing complete
HPV31 genomes showed enhanced levels of HIF-1a
upon treatment with the hypoxia mimic deferoxamine
mesylate (DFO), which resulted from protein stabiliza-
tion and lead to increases in some but not all down-
stream effectors of the hypoxic response, suggesting that
HPV specifically manipulates aspects of the cellular
hypoxic response; both HPV E6 and E7 were able inde-
pendently to enhance induction of HIF-1a upon DFO
treatment [52]. A recent study indicate that, in cell lines
experiments, the HPV E7 protein is responsible for
enhanced HIF-1a activity and enhances HIF-1 depen-
dent transcription by inducing the dissociation of
HDACs from HIF-1a [24].
In our specimens HIF-1a positivity was detected
throughout the analysed fields, not associated with areas
of necrosis and also observed in cells immediately adja-
cent to blood vessels, suggesting an O2-independent reg-
ulatory mechanism. Generally, in infected positive
HPV16 DNA tumors we found increased expression for
HIF-1a, especially for stage I-II and pT1-pT2 tumors,
suggesting a very early event in the development of
HPV-induced OSCC. We also observed that HIF-1a and
HPV16 E7 immunoreactivity were uniform on the same
specimens with a positive correlation of their labeling
indexes which suggests a positive association between
HPV16 E7 and HIF-1a expression in infected positive
HPV16 DNA OSCC.
Conclusions
In our specimens HIF-1a immunoreactivity hints for an
O2-independent regulatory mechanism in infected posi-
tive HPV16 DNA tumors, especially for pT1-T2 and
stage I-II tumors, suggesting a very early involvement in
the development of HPV-induced OSCC. HIF-1a and
HPV16 E7 labeling indexes suggest also a positive asso-
ciation between the two proteins in infected positive
HPV16 DNA OSCC. Finally, it may also be extremely
interesting to investigate an effective way to inhibit
tumor progression in early infected positive HPV16
DNA OSCCs by blocking the activity of HIF-1.
Methods
Patients and Tumor Specimens
The study population was composed of 62 randomly
selected patients who underwent surgical resection for
histologically diagnosed OSCC; tissue samples taken
from the subjects and stored in the archives of the
Rodolico et al. Infectious Agents and Cancer 2011, 6:18
http://www.infectagentscancer.com/content/6/1/18
Page 5 of 8
Department of Sciences for Health Promotion, Section
of Anatomic Pathology, University of Palermo, provided
adequate histological material. Twenty-three of the 62
OSCC were positive for HPV DNA; all 23 HPV DNA
positive tumors contained HPV16 DNA. Forty-seven
cases, 39 negative for HPV DNA and 8 positive for
HPV16 DNA, were selected from our previous work
[53]; others HPV DNA positive samples were excluded
from the study because specific monoclonal antibodies
to HPV E7 protein for immunohistochemistry was avail-
able only for HPV16 type. The 8 HPV16 positive cases
from our previous study were retest to assert their
HPV16 positivity via PCR method from paraffin
embedded archived material. The remaining 15 cases
positive for HPV16 DNA were added from PCR analysis
on other archival material.
The mean age of the 62 patients was 62.14 years (SD
± 9.42), range (29-81); males 20 (35.7%), females 36
(64.3%). Out of 62 OSCCs, 29 were localised on the ton-
gue, 15 on buccal mucosa, 11 on alveolar ridge mucosa
and 7 on the palate.
Informed consent was obtained from all patients and
the IRB of the University of Palermo, Italy, approved the
study.
Histological analysis
Microscopic evaluation was performed by one oral
pathologist (VR), who confirmed OSCC diagnosis and
also determined the score of Histological Grading (HG).
The World Health Organization criteria [54] were used
as follows: grade 1 (G1), well differentiated; grade 2
(G2), moderately differentiated and grade 3 (G3), poorly
differentiated. Grade is dependent on the degree of
prickle formation, keratinization, and overall resem-
blance of carcinoma to normal squamous epithelium.
PCR and sequencing analysis
Each formalin-fixed, paraffin-embedded tissue sample
was processed as described in[55] to obtain DNA sam-
ples to be used in the following PCR analysis. All sam-
ples were checked for DNA quality by amplification of
the human b-globin gene using the couple of primers
PCO3+ (5’CTTCTGACACAACTGTGTTCACTAGC3’)
and PCO4+ (5’TCACCGCAACTTCATCCACGTT-
CACC3’) and tested in duplicate. Three types of con-
trols were included in each reaction series: blank
control, HPV-negative cells Wi as negative control and
HPV18 DNA-positive HeLa cells, in dilutions from
20,000-50,000 down to 2-5 HPV-DNA copies, as posi-
tive control. HPV-DNA was amplified in a nPCR assay
[MY09 (CGTCC(AC)A(AG)(AG)GGA(AT)ACTGATC)
- MY11 (GC(AC)CAGGG(AT)CATAA(CT)AATGG)
degenerated primer pair in combination with GP5
(5’TTTGTTACTGTGGTAGATACTAC3’) - GP6
(5’GAAAAATAAACTGTAAATCATATTC3’) primer
pair] as previously described [56], and amplifications
were performed in a DNA thermal cycler (Mastercycler
gradient, Eppendorf, Hamburg, Germany); amplification
products were analyzed in 1% agarose gel.
HPV genotyping was based on direct sequencing of
MY- or MY/GP-PCR fragments [56]. Amplification pro-
ducts were purified by Microcon YM-100 (Amicon,
Millipore); the sequence of both DNA strands was
determined by the BigDye Ready Reaction Kit (Perkin-
Elmer Applied Biosystem, Foster City, Calif.) in the
automatic sequencer ABI Prism 310 Analyzer (Perkin-
Elmer Applied Biosystem). Alignments were obtained
from the GenBank on-line BLAST server and HPV
sequences were downloaded from the HPV database
http://hpv-web.lanl.gov.
Immunohistochemistry
Tissue samples were fixed in 10% buffered formalin,
dehydrated in ethanol and paraffin-embedded according
to the routine technique. Immunohistochemical analyses
were performed on 3-μm-thick paraffin-embedded sec-
tions of tumors as routine procedure as described in
[57]. Briefly, sections were subsequently exposed to
either mouse monoclonal anti HPV16 E7 oncoprotein
(Invitrogen Corporation, Camarillo, CA, USA), dilution
1:50, for 2 hours at 25°C or rabbit polyclonal anti-HIF-
1a (Novus Biologicals, Littleton, Co, USA), dilution
1:100, for 1 hour at 25°C, or unconjugated rabbit immu-
noglobulins (negative control) for 1 hour at 25°C. Stain-
ing was detected using Novolink Polymer Detection
System, (Novocastra Laboratories, Newcastle Upon
Tyne, UK) according to manufacturer’s instructions and
counterstained with aqueous hematoxylin.
Immunohistochemical evaluation
For the evaluation of HPV16 E7 oncoprotein and HIF-
1a immunoreactions, tissues were examined for evi-
dence of staining with the aid of the NIH ImageJ soft-
ware http://rsbweb.nih.gov/ij. Specimens were observed
under a light microscope (DM4000B with a plan 40×
objective, aperture 0.65, 10× ocular; Leica Microsystems,
Wetzlar, Germany), and images of representative fields
were captured with a digital camera (DFC480; Leica
Microsystems) onto a hard drive disk and then opened
with the ImageJ software to evaluate the indices of posi-
tive staining that was regarded as Labeling Index (LI).
With the aim to use the cell counter technique, positive
and negative stained cells were marked placing different
colors marks by mouse clicking directly from the screen.
For each case a minimum of 103 cells was counted; Ima-
geJ software was then able to automatically generate the
percentage of tumor cells stained with HPV16 E7 and
HIF-1a antibodies. Only epithelial cells were counted
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regardless of localization or intensity of staining. Twenty
random cases were evaluated separately by two different
observers (V.R. and F.A.); since the variation was less
than 5%, the first pathologist’s data were used.
Statistical methods
Continuous variables were analyzed as mean values ±
standard deviation (SD). Rates and proportions were cal-
culated for categorical data. For categorical variables,
differences were analyzed by the c2 test and Fisher exact
test when appropriate. Normality of distribution for
quantitative data was assessed by the Kolmogorov-Smir-
nov test. Differences between two groups were detected
by the unpaired Student’s t-test for continuous variables
with normal distribution. For continuous variable with-
out normal distribution, we used nonparametric tests,
and differences were analyzed by the Mann-Whitney U
test. Correlations among continuous variables were
determined by the use of Spearman test. p < .05 was
considered statistically significant. All analyses were per-
formed with Statistical Package for Social Science (SPSS
for Windows, version 17.0; ©SPSS Inc., Chicago, Ill,
USA).
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